我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

贝那普利与地尔硫卓治疗心脏X综合征患者疗效的比较

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2010年第2期
页码:
240-243
栏目:
临床研究
出版日期:
2010-03-04

文章信息/Info

Title:
Comparison of effect between benazepril and diltiazem in patients with cardiac X-syndrome
作者:
董春; 石娴静; 张新岭
济宁市第一人民医院心脏中心，山东 济宁 272100
Author(s):
DONG Chun;  SHI Xian-jing;  ZNANG Xin-ling
Department of Cardiology, Jining First People’s Hospital, Jining 272100, Shandong, China
关键词:
贝那普利; 地尔硫卓; X综合征; 冠状动脉血流储备; 内皮素-1; 一氧化氮
Keywords:
benazepril;  diltiazem;  cardiac X-syndrome;  coronary flow reserve;  endothelin-1;  nitric oxide
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的: 观察贝那普利与地尔硫卓对心脏X综合征患者的疗效。 方法: 心脏X综合征患者45例接受贝那普利 (22例, 贝那普利组) 或地尔硫卓(23例,地尔硫卓组)治疗，治疗3个月后随访临床情况并复查平板运动试验、冠状动脉血流储备（CFR）及血浆一氧化氮（NO）、血浆内皮素-1（ET-1）的含量。结果: 用药3个月后贝那普利组和地尔硫卓组胸痛例数及最大ST段压低幅度明显减少(分别为P<0.01，P<0.05)，ET-1水平明显下降(均P<0.01)，血浆CFR及NO的水平明显升高(P<0.01或P<0.05)，运动总时间、ST段压低1 mm时间明显延长(P<0.01或P<0.05)。与地尔硫卓组相比贝那普利组胸痛例数及最大ST段压低幅度减少更显著(均P<0.05)，ET-1水平下降更显著（P<0.01），CFR及NO的水平升高更显著(均P<0.05)，运动总时间、ST段压低1 mm时间延长更显著（分别为P<0.01，P<0.05）。结论: 贝那普利与地尔硫卓均能改善心脏X综合征患者的内皮细胞功能提高患者的运动耐量及CFR，且与地尔硫卓相比贝那普利更为有效。
Abstract:
AIM: To investigate the effects of benazepril and diltiazem on patients with cardiac X-syndrome. METHODS: Forty five patients with cardiac X-syndrome were randomly allocated to be treated with benazepril (Group A, n=22) or with diltiazem (Group B, n=23) for 3 months. Clinical presentations, results of treadmill tests, coronary flow reserve (CFR), and levels of endothelin-1 (ET-1) and nitric oxide (NO) were compared before and 3 months after treatment. RESULTS: After the 3-month treatment, the number of episodes of chest pain, ST depression and levels of ET-1 significantly decreased (all P<0.01 vs. before treatment). CFR, as well as NO levels, significantly increased (all P<0.01 vs. before treatment) and total exercise duration as well as time to 1 mm ST segment depression were significantly longer (all P<0.01 vs. before treatment) in benazepril group. After the 3-month treatment, the number of episodes of chest pain, ST depression and levels of ET-1 significantly decreased (all P<0.05 vs. before treatment), CFR significantly increased (P<0.05) and total exercise duration as well as time to 1-mm ST segment depression were significantly longer (all P<0.05 vs. before treatment) in diltiazem group. The number of episodes of chest pain, ST depression and the levels of ET-1 significantly decreased and CFR as well the levels of NO significantly increased (all P<0.05 vs. diltiazem group) and total exercise duration as well as time to 1-mm ST segment depression were significantly longer (all P<0.05 vs. diltiazem group) in benazepril group. CONCLUSION: Benazepril may exert a more positive effect than diltiazem in the improvement of exercise tolerance for patients with cardiac X-syndrome.

参考文献/References

［1］ Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation［J］. Arterioscler Thromb Vasc Biol, 2000, 20(1):61-69.

［2］ Kaski JC, Russo G. Microvascular angina in patients with syndrome X［J］. Z Kardiol, 2000, 89(Suppl 9):121-125.

［3］ Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress［J］. Circ Res, 2000, 87(10):840-844.

［4］ Perticone F, Ceravolo R, Maio R, et al. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients［J］. Cardiovasc Res, 1999, 41(1):299-306.

［5］ Yamamoto S, James TN, Kawamura K, et al. Cardiocytic apoptosis and capillary endothelial swellingas morphological evidence of myocardial ischemia in ventricular biopsies from patients with angina and normal coronary arteriograms［J］. Coron Artery Dis, 2002, 13(1):25-35.

［6］ Chen JW, Hsu NW, Wu TC, et al. Long-term angiotensin- converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X［J］. Am J Cardiol, 2002, 90(9):974-982.

［7］ Pizzi C, Manfrini O, Fontana F, et al. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac syndrome X［J］. Circulation, 2004, 109(1):53-58.

备注/Memo

备注/Memo:
收稿日期：2008-5-31.作者简介：董春，主治医师Email:xinling78@yahoo.com.cn
更新日期/Last Update: 2010-03-05